Literature DB >> 25512016

Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy.

L Mo1, J He, Q Yue, B Dong, X Huang.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: The concomitant administration of atorvastatin and cyclosporine has been shown to increase the serum concentration of 3-hydroxy-3-methylglutaryl coenzyme A, which may be associated with the elevation of creatine kinase and an increased risk of myopathy. Our objective is to report on a case of statin-induced myopathy associated with concomitant use of cyclosporine and other contributing factors. CASE
SUMMARY: An 88-year-old Chinese male patient with comorbidities received polypharmacy treatment, including atorvastatin and cyclosporine. After the dosage of cyclosporine was increased to 300 mg every day for 8 months, the patient developed body pain and leg weakness, with a serum creatine kinase increase and evidence on magnetic resonance imaging of muscle oedema. WHAT IS NEW AND
CONCLUSION: Cyclosporine is a moderate inhibitor of the cytochrome P450 CYP3A4 isoenzyme, which is known to increase the serum level of atorvastatin. We hypothesized that the pharmacological and pharmacokinetic properties of atorvastatin-induced myopathy are the result of its interaction with high dosage of cyclosporine.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  creatine kinase; cyclosporine; drug-drug interactions; myopathy; statin

Mesh:

Substances:

Year:  2014        PMID: 25512016     DOI: 10.1111/jcpt.12240

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  5 in total

1.  Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.

Authors:  Li Chen; Cai Cheng; Bicui Chen; Yue Zhao; Jiming Zhang; Bin Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-11-14       Impact factor: 2.953

2.  Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites.

Authors:  Xue Bai; Bin Zhang; Ping Wang; Guan-Lei Wang; Jia-Li Li; Ding-Sheng Wen; Xing-Zhen Long; Hong-Shuo Sun; Yi-Bin Liu; Min Huang; Shi-Long Zhong
Journal:  Acta Pharmacol Sin       Date:  2018-06-27       Impact factor: 6.150

Review 3.  Drug-Induced Kidney Injury in the Elderly.

Authors:  Sana Khan; Valentina Loi; Mitchell H Rosner
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

Review 4.  Rhabdomyolysis after co-administration of a statin and fusidic acid: an analysis of the literature and of the WHO database of adverse drug reactions.

Authors:  Thomas Deljehier; Antoine Pariente; Ghada Miremont-Salamé; Françoise Haramburu; Linh Nguyen; Sébastien Rubin; Claire Rigothier; Hélène Théophile
Journal:  Br J Clin Pharmacol       Date:  2018-02-26       Impact factor: 4.335

5.  Uncover the Underlying Mechanism of Drug-Induced Myopathy by Using Systems Biology Approaches.

Authors:  Dong Li; Aixin Li; Hairui Zhou; Xi Wang; Peng Li; Sheng Bi; Yang Teng
Journal:  Int J Genomics       Date:  2017-07-31       Impact factor: 2.326

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.